2 min read

Caplin Point Laboratories Moat Analysis: Score & Risks

Moat Note · First-pass

Caplin Point Laboratories Ltd.

A first-pass moat teardown of Caplin Point Laboratories Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

Moat & Margin16 Aug 2026 First-pass · ~3 min
5.45 / 10
NARROWProcess/Data-led

First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Caplin Point Laboratories Ltd. scores 5.45 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown

Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.

D3Cost Advantage6.5
M · Mechanism Verified verbatim

“Affordability: Caplin Point is leveraging its established cost leadership to provide affordable medicines widening the market and its corresponding share.”

Caplin Point Laboratories Ltd. · Annual Report · p.10
D1Network Effects5.7
M · Mechanism Verified verbatim

“With over 5,000 product licenses globally and our unique distribution-led business model, we have fortified our leadership position in these regions.”

Caplin Point Laboratories Ltd. · Annual Report · p.17
D4Price Discretion5.7
M · Mechanism Verified verbatim

“Our EBITDA margin of 33.32% in 2019-20 was among the highest in India's pharmaceutical sector”

Caplin Point Laboratories Ltd. · Annual Report · p.11
D5Intangible Assets5.2
M · Mechanism Verified verbatim

“Caplin Point is addressing the US opportunity with an attractive pipeline of proprietary ANDAs while attracting CMO opportunities from MNCs”

Caplin Point Laboratories Ltd. · Annual Report · p.17
D6Efficient Scale4.8
M · Mechanism Verified verbatim

“Out of 21 products filed in Mexico, 12 products are from Chinese companies that are EU and U.S.A approved facility.”

Caplin Point Laboratories Ltd. · Earnings Call · p.3
D2Switching Costs4.5
No verified filing quote surfaced for this dimension in the first-pass evidence sweep.
D7Counter-PositioningExcluded
Excluded for this archetype.
D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate

The barrier gate — first-pass

Replication — can a rival copy it?6.5
How hard it is for a rival to copy the edge (first-pass estimate).
Bypass — can a rival route around it?5.0
How easily a rival can route around the edge (first-pass estimate).

Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.

What would change our mind
  1. Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.

  2. The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.

  3. Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.